Literature DB >> 8238690

Screening for colorectal neoplasia: physicians' adherence to complete diagnostic evaluation.

R E Myers1, A M Balshem, T A Wolf, E A Ross, L Millner.   

Abstract

This prospective study was done in a health maintenance organization colorectal cancer screening program to determine whether 166 persons found to have abnormal fecal occult blood test results typically underwent complete diagnostic evaluation (i.e., either colonoscopy or barium enema x-ray plus flexible sigmoidoscopy). Chart audit data show that 137 (82%) subjects contacted a physician to discuss follow-up. A complete diagnostic evaluation was recommended to only 52 (38%) patients who talked with a physician. Forty-two (81%) patients who were advised to get a complete diagnostic evaluation actually complied. Significant differences in clinical findings were observed for patients who did and did not have a complete diagnostic evaluation.

Entities:  

Mesh:

Year:  1993        PMID: 8238690      PMCID: PMC1694870          DOI: 10.2105/ajph.83.11.1620

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  15 in total

1.  Overconfidence among physicians and nurses: the 'micro-certainty, macro-uncertainty' phenomenon.

Authors:  A O Baumann; R B Deber; G G Thompson
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

2.  The quality of medical evidence: implications for quality of care.

Authors:  D M Eddy; J Billings
Journal:  Health Aff (Millwood)       Date:  1988       Impact factor: 6.301

3.  Mammography and palpable cancer of the breast.

Authors:  S Edeiken
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

4.  Screening mammography--potential problems on the horizon.

Authors:  F M Hall
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

5.  Fecal occult blood screening and evaluation for a positive test.

Authors:  S J Brendler; S W Tolle
Journal:  West J Med       Date:  1987-01

6.  Variations in physician practice: the role of uncertainty.

Authors:  D M Eddy
Journal:  Health Aff (Millwood)       Date:  1984       Impact factor: 6.301

7.  Mass screening for colorectal cancer.

Authors:  I T Khubchandani; M C Karamchandani; F S Kleckner; J A Sheets; J J Stasik; L Rosen; R D Riether
Journal:  Dis Colon Rectum       Date:  1989-09       Impact factor: 4.585

8.  Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects.

Authors:  J Kewenter; S Björk; E Haglind; L Smith; J Svanvik; C Ahrén
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

9.  A mass screening program for colorectal cancer using chemical testing for occult blood in the stool.

Authors:  D P Winchester; J H Shull; E F Scanlon; J V Murrell; C Smeltzer; P Vrba; M Iden; D H Streelman; R Magpayo; J W Dow; J Sylvester
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

Review 10.  Occult blood screening for colorectal carcinoma: a critical review.

Authors:  J B Simon
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

View more
  14 in total

Review 1.  Interventions to improve follow-up of abnormal findings in cancer screening.

Authors:  Roshan Bastani; K Robin Yabroff; Ronald E Myers; Beth Glenn
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

2.  Effectiveness of complete diagnostic examination in clinical practice settings.

Authors:  Masahito Jimbo; Birgit Meyer; Terry Hyslop; James Cocroft; Barbara J Turner; David S Weinberg; Ronald E Myers
Journal:  Cancer Detect Prev       Date:  2006-11-17

3.  Screening for colorectal cancer: the role of the general practitioner.

Authors:  G Launoy; C Herbert; M Gignoux
Journal:  Am J Public Health       Date:  1994-10       Impact factor: 9.308

4.  Long-term outcomes following positive fecal occult blood test results in older adults: benefits and burdens.

Authors:  Christine E Kistler; Katharine A Kirby; Delia Lee; Michele A Casadei; Louise C Walter
Journal:  Arch Intern Med       Date:  2011-05-09

5.  Lack of follow-up after fecal occult blood testing in older adults: inappropriate screening or failure to follow up?

Authors:  Charlotte M Carlson; Katharine A Kirby; Michele A Casadei; Melissa R Partin; Christine E Kistler; Louise C Walter
Journal:  Arch Intern Med       Date:  2010-10-11

6.  The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.

Authors:  Rachel Gingold-Belfer; Haim Leibovitzh; Doron Boltin; Nidal Issa; Tsachi Tsadok Perets; Ram Dickman; Yaron Niv
Journal:  United European Gastroenterol J       Date:  2019-02-06       Impact factor: 4.623

7.  Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results.

Authors:  Hardeep Singh; Himabindu Kadiyala; Gayathri Bhagwath; Anila Shethia; Hashem El-Serag; Annette Walder; Maria E Velez; Laura A Petersen
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

8.  Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation.

Authors:  Masahito Jimbo; Ronald E Myers; Birgit Meyer; Terry Hyslop; James Cocroft; Barbara J Turner; David S Weinberg
Journal:  Ann Fam Med       Date:  2009 Jan-Feb       Impact factor: 5.166

9.  Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization.

Authors:  Diana L Miglioretti; Carolyn M Rutter; Susan Carol Bradford; Ann G Zauber; Larry G Kessler; Eric J Feuer; David C Grossman
Journal:  Med Care       Date:  2008-09       Impact factor: 2.983

10.  The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation.

Authors:  John A Conti; Timothy J Kendall; Adrian Bateman; Thomas A Armstrong; Andrew Papa-Adams; Qian Xu; Graham Packham; John N Primrose; R Christopher Benyon; John P Iredale
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.